United States · Financial press · Barron's
Summit’s FDA Setback Is a Reality Check for Next-Gen Cancer Drugs
Detailed summary
Summit Therapeutics stock sinks as regulators decline to approve ivonescimab, a next-generation cancer therapy backed by AstraZeneca.
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.barrons.com)